Four hundred attendees are expected from throughout Europe and elsewhere. An international faculty, including some of the most respected and pioneering experts dealing with these rare cancers, has developed the conference programme.
Who should attend?
- medical oncologists
- radiation therapists
- molecular biologists
who are involved with the research and treatment of soft tissue sarcomas and GIST.
- Gastrointestinal sarcoma (GIST) – Sensitive disease
- Gastrointestinal sarcoma (GIST) – Resistant disease
- Desmoid tumours
- Soft tissue sarcomas: Localised disease
- Molecularly-targeted soft tissue sarcomas
- Personalised treatment for soft tissue sarcomas
- Uterine sarcoma
- Issues in some neglected types of sarcomas
- How to study sarcomas
Benefits in attending:
This conference aims to provide a comprehensive overview of current medical therapy for soft tissue sarcomas and GIST, with a focus on personalised clinical approach from a multidisciplinary aspect and the molecular and pathological bases of these diseases. With this goal, lectures on molecular biology and those on treatment will be grouped together in the same sessions. These will be based on the various anatomical regions from which sarcomas can arise throughout the body, thus going from the classical limb locations to retroperitoneum, from visceral (including GIST) to gynaecological, thoracic, muscles, peripheral nerves, vascular primary sites. How the next-generation sequencing will change the current landscape, as well as topics on emerging targets and new drugs are incorporated into main sessions. The audience will take home an updated overview of where do we currently stand with personalising the treatment for soft tissue sarcomas and GIST and where we are going to, thanks to a top-level faculty, incorporating the major clinical and translational experts from the worldwide sarcoma community.
- To understand and learn some histological and molecular aspects of soft tissue sarcomas and GIST which are relevant for clinical practice
- To understand the implications of a multidisciplinary approach in the management of soft tissue sarcomas and GIST
- To present an update on how to personalise the current state-of-the-art management of soft tissue sarcoma and GIST, which will be approached comprehensively according to the anatomic site of origin
The programme of this event will be:
- Accredited with ESMO-MORA category 1 points
- Submitted for CME accreditation to the EACCME (Accreditation Council for Continuing Medical Education). EACCME is an institution of the European Union of Medical Specialists (UEMS). These credits are also recognised by the American Medical Association (AMA) as Physician’s Recognition Award (AMA PRA Category 1 credits)
There will be no abstract submission for this meeting.
The conference webcasts will include all the session of the official programme, where speaker permission is granted ,and will be available on this website and OncologyPRO for ESMO members.